medRxiv preprint doi: https://doi.org/10.1101/2021.05.20.21257456; this version posted May 25, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Characterization of mitochondrial DNA quantity and quality in the human aged and Alzheimer’s disease brain Hans-Ulrich Klein1,2,*, Caroline Trumpff3, Hyun-Sik Yang4, Annie J. Lee2, Martin Picard3,5, David A. Bennett6, Philip L. De Jager1,2,* 1Center for Translational & Computational Neuroimmunology, Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA 2Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY 10032, USA 3Division of Behavioral Medicine, Department of Psychiatry, Columbia University Irving Medical Center, New York, NY 10032, USA 4Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA 5Merritt Center and Columbia Translational Neuroscience Initiative, Department of Neurology, Columbia University Irving Medical Center, New York, NY 10032, USA 6Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL 60612, USA *Correspondance:
[email protected] (HUK),
[email protected] (PLD) Summary Mitochondrial dysfunction is a feature of neurodegenerative diseases, including Alzheimer’s disease (AD). Using whole-genome sequencing, we assessed mitochondrial DNA (mtDNA) heteroplasmy levels and mtDNA copy number (mtDNAcn) in 1,361 human brain samples of five brain regions from three studies. Multivariable analysis of ten common brain pathologies identified tau pathology in the dorsolateral prefrontal cortex and TDP-43 pathology in the posterior cingulate cortex as primary drivers of reduced mtDNAcn in the aged human brain.